At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 332 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, 2-Injection, 52-Week Study to Evaluate the Efficacy and Safety of Intra-articular Injections of CNTX-4975-05 in Subjects With Chronic, Moderate-to-severe Osteoarthritis Knee Pain
In Brief
A Phase 3 clinical trial evaluating Placebo and CNTX-4975-05 for Osteoarthritis, Knee. Completed, enrolled 332 participants across 30 sites.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, 2-injection, 52-week study to evaluate the efficacy and safety of intra-articular injections of CNTX-4975-05 in subjects with chronic, moderate-to-severe osteoarthritis knee pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartSep 2018
Primary CompletionJun 2020
TodayJul 2026
First PostedSep 7, 2018
Enrollment StartSep 9, 2018
Primary CompletionJun 11, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.8 years ago
Interventions
Placebodrug
Receiving Placebo Injection
CNTX-4975-05drug
Receiving CNTX-4975-05 Injection